See more : Landing International Development Limited (0582.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Instil Bio, Inc. (TIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Instil Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Imagion Biosystems Limited (IBXXF) Income Statement Analysis – Financial Results
- Maxim Integrated Products, Inc. (0JZM.L) Income Statement Analysis – Financial Results
- Jollibee Foods Corporation (JBFCY) Income Statement Analysis – Financial Results
- Anglo American plc (AAL.L) Income Statement Analysis – Financial Results
- B&M European Value Retail S.A. (BMRPF) Income Statement Analysis – Financial Results
Instil Bio, Inc. (TIL)
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 138.00K | 0.00 |
| Cost of Revenue | 4.76M | 5.99M | 2.75M | 0.00 | 20.00K |
| Gross Profit | -4.76M | -5.99M | -2.75M | 138.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 39.60M | 141.06M | 107.25M | 19.40M | 4.03M |
| General & Administrative | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Other Expenses | 72.01M | -564.00K | -1.20M | -4.66M | -5.00K |
| Operating Expenses | 85.79M | 203.29M | 155.56M | 33.78M | 6.59M |
| Cost & Expenses | 90.54M | 203.29M | 155.56M | 33.78M | 6.59M |
| Interest Income | 8.87M | 3.66M | 0.00 | 70.00K | 68.00K |
| Interest Expense | 5.21M | 1.88M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.76M | 5.99M | 2.75M | 256.00K | 20.00K |
| EBITDA | -146.12M | -217.38M | -154.00M | -33.39M | -6.50M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -24,660.14% | 0.00% |
| Operating Income | -159.17M | -226.46M | -155.56M | -33.64M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -24,379.71% | 0.00% |
| Total Other Income/Expenses | 3.08M | 1.21M | -1.20M | -3.94M | 63.00K |
| Income Before Tax | -156.09M | -225.25M | -156.76M | -37.59M | -6.52M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -27,236.96% | 0.00% |
| Income Tax Expense | 0.00 | -2.07M | 39.00K | 151.00K | -68.00K |
| Net Income | -156.09M | -223.18M | -156.79M | -37.74M | -6.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -27,346.38% | 0.00% |
| EPS | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| EPS Diluted | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| Weighted Avg Shares Out | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
| Weighted Avg Shares Out (Dil) | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
Till Capital Reports First Quarter Earnings of $2.0 Million
Source: https://incomestatements.info
Category: Stock Reports